Non Squamous Non Small Cell Lung Cancer MedDRA version: 9.1 Level: LLT Classification code 10029520 MedDRA version: 9.1 Level: LLT Classification code 10029520
Conditions
Interventions
Pharmaceutical Form: Powder for solution for injection
INN or Proposed INN: Pemetrexed
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 100-
Pharmaceutical Form: Po
Sponsors
Eli Lilly and Company Limited
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: [1] Histologic diagnosis of NSCLC defined as other than predominantly squamous cell histology (squamous cell and/or mixed small cell, non-small cell histology is not permitted). [2] Stage IIIAN2 disease (T1aN2, T1bN2, T2aN2, T2bN2, and T3N2) (except pancoast tumors and bronchoalveolar carcinoma) as defined by the American Joint Committee on Cancer Staging Criteria for Lung Cancer. [3] Tumor considered potentially resectable with no evidence of extrathoracic metastatic disease. [4] ECOG PS of 0 or 1. [5] No prior surgery, radiotherapy, systemic chemotherapy, immunotherapy, targeted, or biological therapy for NSCLC. [6] At least 1 unidimensionally measurable lesion meeting RECIST criteria version 1.1 (at least 10 mm in longest diameter [LD] by CT scan [slice thickness 5mm], or at least 20 mm LD by chest X-ray). For malignant lymph nodes, at least 15 mm in short axis when assessed by CT scan (slice thickness 5 mm). PET scans and ultrasounds may not be used for tumor measurements. [7] Estimated life expectancy of at least 6 months [8] Patient compliance and geographic proximity that allow adequate follow-up. [9] Adequate organ function including the following: Adequate bone marrow reserve: absolute neutrophil (segmented and bands) count (ANC) > or =1.5 x 109/L, platelets > or =100 x 109/L, and hemoglobin > or = 9 g/dL. Hepatic: bilirubin or = 45 mL/min based on the original weight-based Cockroft and Gault formula and serum creatinine or =1.2 L. [15] Patients must be fit for surgery at time on enrollment. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: [16] Are currently enrolled in, or discontinued within the last 30 days from, a clinical trial involving an investigational drug or device or off-label use of a drug or device (other than the study drug/device used in this study), or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study. [17] Have previously completed or withdrawn from this study or any other study investigating pemetrexed. [18] Have a serious concomitant systemic disorder (for example, active infection including human immunodeficiency virus) that, in the opinion of the investigator, would compromise the patient’s ability to adhere to the protocol. [19] Have a serious cardiac condition, such as myocardial infarction within 6 months, angina, or heart disease, as defined by the New York Heart Association Class III or IV. [20] Have had a prior malignancy other than NSCLC, carcinoma in situ of the cervix, or nonmelanoma skin cancer, unless that prior malignancy was diagnosed and definitively treated at least 5 years previously with no subsequent evidence of recurrence. Patients with a history of low grade (Gleason score 5%) weight loss within 6 months of enrollment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: Assess the antitumor activity of pemetrexed in combination with cisplatin, as measured by Overall Response Rate after preoperative chemotherapy, in patients with stage IIIAN2 nonsquamous NSCLC;Secondary Objective: - Assess pathological complete remission rate after surgery, median progression-free survival (PFS), and median overall survival (OS) - Assess tumor downstaging - Characterize quantitative and qualitative toxicities - Assess the expression of biomarkers of interest and their correlation with Overall Response Rate - Assess the expression of biomarkers and their correlation with PFS and OS - Compare baseline expression of biomarkers with the expression of the same biomarkers after 3 cycles of pemetrexed/cisplatin chemotherapy;Primary end point(s): Overall Response rate defined as the proportion of patients whose response is Complete Response or Partial Response | — |
Countries
Italy
Outcome results
None listed